Subcutaneous immunotherapy with mannan-conjugated birch pollen allergens shows long-term effects already after 2 years of treatment by inducing a significant immune response in birch pollen allergic patients

Abstract

Allergen immunotherapies aim to change the immune system in order to alleviate allergy symptoms in the long term. These therapies usually last several years, but first effects can already be detected after 1-2 years. Here, we determine the immunologic effects of 10.000 mTU/mL mannan-conjugated birch pollen allergen (T502).